Literature DB >> 7692083

Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.

S Li1, V Polonis, H Isobe, H Zaghouani, R Guinea, T Moran, C Bona, P Palese.   

Abstract

Expression vectors based on DNA or plus-stranded RNA viruses are being developed as vaccine carriers directed against various pathogens. Less is known about the use of negative-stranded RNA viruses, whose genomes have been refractory to direct genetic manipulation. Using a recently described reverse genetics method, we investigated whether influenza virus is able to present antigenic structures from other infectious agents. We engineered a chimeric influenza virus which expresses a 12-amino-acid peptide derived from the V3 loop of gp120 of human immunodeficiency virus type 1 (HIV-1) MN. This peptide was inserted into the loop of antigenic site B of the influenza A/WSN/33 virus hemagglutinin (HA). The resulting chimeric virus was recognized by specific anti-V3 peptide antibodies and a human anti-gp120 monoclonal antibody in both hemagglutination inhibition and neutralization assays. Mice immunized with the chimeric influenza virus produced anti-HIV antibodies which were able to bind to synthetic V3 peptide, to precipitate gp120, and to neutralize MN virus in human T-cell culture system. In addition, the chimeric virus was also capable of inducing cytotoxic T cells which specifically recognize the HIV sequence. These results suggest that influenza virus can be used as an expression vector for inducing both B- and T-cell-mediated immunity against other infectious agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692083      PMCID: PMC238104     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Mutational analysis of the promoter required for influenza virus virion RNA synthesis.

Authors:  X Li; P Palese
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells.

Authors:  P M Taylor; J Davey; K Howland; J B Rothbard; B A Askonas
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.

Authors:  I A Wilson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

4.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

5.  Complete sequence analysis shows that the hemagglutinins of the H0 and H2 subtypes of human influenza virus are closely related.

Authors:  A L Hiti; A R Davis; D P Nayak
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

6.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.

Authors:  P L Nara; W C Hatch; N M Dunlop; W G Robey; L O Arthur; M A Gonda; P J Fischinger
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

Authors:  J R Bennink; J W Yewdell; G L Smith; C Moller; B Moss
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

8.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Characterization and in vivo distribution of influenza-virus-specific T-lymphocytes in the murine respiratory tract.

Authors:  M R McDermott; A E Lukacher; V L Braciale; T J Braciale; J Bienenstock
Journal:  Am Rev Respir Dis       Date:  1987-01

10.  In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific.

Authors:  A E Lukacher; V L Braciale; T J Braciale
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  36 in total

1.  Downstream sequences influence the choice between a naturally occurring noncanonical and closely positioned upstream canonical heptameric fusion motif during bovine coronavirus subgenomic mRNA synthesis.

Authors:  A Ozdarendeli; S Ku; S Rochat; G D Williams; S D Senanayake; D A Brian
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Budding capability of the influenza virus neuraminidase can be modulated by tetherin.

Authors:  Mark A Yondola; Fiona Fernandes; Alan Belicha-Villanueva; Melissa Uccelini; Qinshan Gao; Carol Carter; Peter Palese
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

3.  Highly stable expression of a foreign gene from rabies virus vectors.

Authors:  T Mebatsion; M J Schnell; J H Cox; S Finke; K K Conzelmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein.

Authors:  M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.

Authors:  M R Castrucci; S Hou; P C Doherty; Y Kawaoka
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Baculovirus surface display: construction and screening of a eukaryotic epitope library.

Authors:  W Ernst; R Grabherr; D Wegner; N Borth; A Grassauer; H Katinger
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

8.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Expression and characterization of virus-like particles containing rubella virus structural proteins.

Authors:  Z Qiu; D Ou; T C Hobman; S Gillam
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.

Authors:  N L Davis; K W Brown; R E Johnston
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.